X线修复交叉互补组1(XRCC1)是碱基切除修复的关键贡献者,并且其失调与各种人类恶性肿瘤的致癌作用有关。然而,全面的泛癌症分析,调查预后价值,免疫功能,和XRCC1的表观遗传关联仍然缺乏。为了解决这个知识差距,我们采用生物信息学技术对33种癌症进行了系统调查.我们的分析包括XRCC1表达水平,预后和诊断意义,表观遗传概况,免疫和分子亚型,肿瘤突变负担(TMB),微卫星不稳定性(MSI),免疫检查点,和免疫浸润,利用来自TCGA的数据,GTEx,CELL,人类蛋白质图谱,Ualcan,和cBioPortal数据库。值得注意的是,XRCC1与不同肿瘤的预后呈正相关和负相关。表观遗传学分析揭示了XRCC1表达与10种癌症类型的DNA甲基化模式之间的关联。以及增强的磷酸化。此外,XRCC1表达在大多数肿瘤中显示与TMB和MSI的关联。有趣的是,XRCC1基因表达与免疫细胞浸润水平呈负相关,除了在大多数癌症中与M1和M2巨噬细胞和单核细胞呈正相关。此外,我们观察到XRCC1与免疫检查点基因表达水平之间存在显著相关性.最后,我们的发现暗示XRCC1参与DNA复制和修复过程,阐明其致癌作用的确切机制。总的来说,我们的研究强调了XRCC1作为预后和免疫学泛癌症生物标志物的潜力,从而为肿瘤免疫治疗提供了新的靶点。
X-ray repair cross-complementation group 1 (XRCC1) is a pivotal contributor to base excision repair, and its dysregulation has been implicated in the oncogenicity of various human malignancies. However, a comprehensive pan-cancer analysis investigating the prognostic value, immunological functions, and epigenetic associations of XRCC1 remains lacking. To address this knowledge gap, we conducted a systematic investigation employing bioinformatics techniques across 33 cancer types. Our analysis encompassed XRCC1 expression levels, prognostic and diagnostic implications, epigenetic profiles, immune and molecular subtypes, Tumor Mutation Burden (TMB), Microsatellite Instability (MSI), immune checkpoints, and immune infiltration, leveraging data from TCGA, GTEx, CELL, Human Protein Atlas, Ualcan, and cBioPortal databases. Notably, XRCC1 displayed both positive and negative correlations with prognosis across different tumors. Epigenetic analysis revealed associations between XRCC1 expression and DNA methylation patterns in 10 cancer types, as well as enhanced phosphorylation. Furthermore, XRCC1 expression demonstrated associations with TMB and MSI in the majority of tumors. Interestingly, XRCC1 gene expression exhibited a negative correlation with immune cell infiltration levels, except for a positive correlation with M1 and M2 macrophages and monocytes in most cancers. Additionally, we observed significant correlations between XRCC1 and immune checkpoint gene expression levels. Lastly, our findings implicated XRCC1 in DNA replication and repair processes, shedding light on the precise mechanisms underlying its oncogenic effects. Overall, our study highlights the potential of XRCC1 as a prognostic and immunological pan-cancer biomarker, thereby offering a novel target for tumor immunotherapy.